Outcomes
We assessed the effi cacy of rolapitant over a period of 120 h after initiation of chemotherapy. The primary effi cacy endpoint was the proportion of patients achieving a complete response (defi ned as no emesis or use of rescue medication) in the delayed phase (>24–120 h after initiation of chemotherapy).
Patients recorded all events of vomiting and use of rescue medication in a daily diary during the entire 120 h study period. The primary assessment of effi cacy was based on responses recorded in these diaries during cycle 1